Search Result

Results for "

Glucagon Receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	GCGR (75) Cytochrome P450 (2) Free Fatty Acid Receptor (1) FXR (2) GLP Receptor (34) Insulin Receptor (1) Isotope-Labeled Compounds (2) Melatonin Receptor (1) Nuclear Hormone Receptor 4A/NR4A (2) Somatostatin Receptor (4)
By Research Areas:	Cancer (2) Endocrinology (4) Inflammation/Immunology (5) Metabolic Disease (98) Neurological Disease (8)

110

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: GCGR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50159

Glucagon receptor antagonists-3	GCGR	Metabolic Disease
Glucagon receptor antagonists-3 is a highly potent glucagon receptor antagonist.

HY-50158

Glucagon receptor antagonists-2	GCGR	Metabolic Disease
Glucagon receptor antagonists-2 is a highly potent glucagon receptor antagonist.

HY-10036

Glucagon receptor antagonists-1	GCGR	Metabolic Disease
Glucagon receptor antagonists-1 is a highly potent glucagon receptor antagonist.

HY-19947

PF-06291874 1 Publications Verification Glucagon Receptor antagonists-4	GCGR	Metabolic Disease
PF-06291874 is a highly potent, non-peptide and orally active **glucagon receptor** antagonist. PF-06291874 is under the study for type 2 diabetes mellitus (T2DM) .

HY-P3506

Retatrutide 1 Publications Verification LY3437943	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) is a triple agonist peptide of *the glucagon* receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .

HY-P3506A

Retatrutide TFA 1 Publications Verification LY3437943 TFA	GLP Receptor GCGR	Metabolic Disease
Retatrutide (LY3437943) TFA is a triple agonist peptide of *the glucagon* receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .

HY-128781

Glucagon receptor antagonists-5	GCGR	Metabolic Disease
Glucagon receptor antagonists-5 (compound 13K) is a potent and orally bioavailable indazole-based **glucagon receptor antagonist (K_i*=32 nM). Glucagon* receptor antagonists-5 has potential for the treatment of type 2 diabetes mellitus (T2DM) .

HY-119739

Skyrin	GCGR	Metabolic Disease Cancer
Skyrin is an anthraquinone compound that can be isolated from almond fruit. Skyrin is a receptor-selective *glucagon* antagonist. Skyrin can inhibit the growth of tumor cells .

HY-P10327

PP18	GLP Receptor	Metabolic Disease
PP18 is a novel OXM-based dual GLP-1 and glucagon receptor agonist with EC₅₀ values of 0.487 nM target hGLP-1R and 0.188 nM target hGcgR .

HY-P3506B

Retatrutide acetate LY3437943 acetate	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) acetate is a triple agonist peptide of *the glucagon* receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .

HY-19374

BAY-27-9955	GCGR	Metabolic Disease
BAY-27-9955 is an orally active non-peptide **glucagon receptor** antagonist. Bay 27-9955 competitively blocks the interaction of glucagon with the human glucagonreceptor at an IC₅₀ value of 110 nM. BAY-27-9955 can be used for the study of type 2 diabetes .

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P4146A

Survodutide TFA BI 456906 TFA	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P3375

Mazdutide IBI-362; LY-3305677; OXM-3	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .

HY-P3375A

Mazdutide TFA IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .

HY-50675

GRA Ex-25	GCGR	Metabolic Disease
GRA Ex-25 is an inhibitor of **glucagon receptor, with IC₅₀** of 56 and 55 nM for rat and human glucagon receptors, respectively.

HY-P4672

(Met(O)27)-Glucagon (1-29) (human, rat, porcine)	GCGR	Metabolic Disease
(Met(O)27)-Glucagon (1-29) (human, rat, porcine) is a modified glucagon. (Met(O)27)-Glucagon (1-29) (human, rat, porcine) has the same maximum glucose-synthesizing activity in rat hepatocytes as native glucagon, but it is less potent, suggesting a crucial role of methionine in the binding of glucagon to its hepatic receptor .

HY-P1143

[Des-His1,Glu9]-Glucagon amide	GCGR	Metabolic Disease
[Des-His1,Glu9]-Glucagon amide is a potent and peptide antagonist of the **glucagon receptor, with a pA₂** of 7.2. [Des-His1,Glu9]-Glucagon amide is potentially useful in the study of the pathogenesis of diabetes .

HY-P1143A

[Des-His1,Glu9]-Glucagon amide TFA	GCGR	Metabolic Disease
[Des-His1,Glu9]-Glucagon amide TFA is a potent and peptide antagonist of the **glucagon receptor, with a pA₂** of 7.2. [Des-His1,Glu9]-Glucagon amide TFA is potentially useful in the study of the pathogenesis of diabetes .

HY-145458

GLP-1 receptor agonist 9	GCGR	Metabolic Disease
GLP-1 receptor agonist 9 is a GLP-1 receptor agonist, example 7, extracted from WO2020234726 A1 .

HY-103547

L-168049	GCGR	Metabolic Disease
L-168049 is a potent, selective, orally active and non-competitive **glucagon receptor antagonist with IC₅₀*s of 3.7 nM, 63 nM, and 60 nM for human, murine, and canine glucagon* receptors, respectively .

HY-12735

SCH 900822	GCGR	Metabolic Disease Endocrinology
SCH 900822 is a potent and selective glucagon receptor (hGCGR) antagonist that blocks the binding of glucagon to its receptor, thereby reducing hepatic glycogenolysis and gluconeogenesis, thereby lowering blood glucose production. SCH 900822 can be used in the study of type 2 diabetes .

HY-P3608

[Des-His1,Glu9] Glucagon	GCGR	Metabolic Disease
[Des-His1,Glu9] Glucagon is a potent glucagon receptor system peptide antagonist. [Des-His1,Glu9] Glucagon enhances the glucose-stimulated release of insulin from pancreatic islet cells. [Des-His1,Glu9] Glucagon can be used to research diabetes .

HY-50663

MK 0893 5 Publications Verification	GCGR	Metabolic Disease
MK 0893 is a potent and selective **glucagon receptor antagonist with an IC₅₀** of 6.6 nM.

HY-164040

Zavolosotine	Somatostatin Receptor	Metabolic Disease
Zavolosotine (Compound 1) is an orally active agonist for somatostatin receptor type 5 (SST5) with EC₅₀ <1 nM. Zavolosotine inhibits insulin and glucagon secretion, increases levels of glucagon in blood in rat model .

HY-148844

GCGR antagonist 2	GCGR	Metabolic Disease
GCGR antagonist 2, a Furan-2-carbohydrazide, is an orally active **glucagon receptor antagonist. GCGR antagonist 2 binds to hGluR with an K_d** value of 2.3 nM, and inhibits rat receptor with an IC₅₀ value of 0.43 nM. GCGR antagonist 2 inhibits glucagon-stimulated glycogenolysis .

HY-P3388

Utreglutide	GCGR	Metabolic Disease
Utreglutide is a potent **glucagon-like peptide 1 (GLP-1) receptor** agonit .

HY-P10592

Bofanglutidum Bofanglutide	GLP Receptor	Metabolic Disease
Bofanglutide (Bofanglutidum) is a glucagon-like peptide 1 (GLP-1) receptor agonist .

HY-P10032

NN1177 NNC9204-1177	GCGR GLP Receptor Cytochrome P450	Metabolic Disease
NN1177 is a long-acting **GLP-1/glucagon receptor** co-agonist. NN1177 can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .

HY-112679

GLP-1 receptor agonist 2	GCGR	Others
GLP-1 receptor agonist 2 is a glucagon-like peptide-1 receptor (GLP-1R) agonist.

HY-162433

I-070	GLP Receptor	Metabolic Disease
I-070 is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC₅₀ of 0.0187 nM .

HY-162434

I-128	GLP Receptor	Metabolic Disease
I-128 is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC₅₀ of 0.0122 nM .

HY-155147

GLP-1 receptor agonist 13	GLP Receptor	Metabolic Disease
GLP-1 receptor agonist 13 (compound (S)-9) is a glucagon GLP-1 receptor agonist with EC₅₀ of 76 nM .

HY-P1145

Glucagon-like peptide 1 (1-37), human HuGLP-1	GCGR	Metabolic Disease
Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.

HY-P1145A

Glucagon-like peptide 1 (1-37), human TFA 1 Publications Verification HuGLP-1 TFA	GCGR	Metabolic Disease
Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor.

HY-P10018

Bamadutide SAR425899	GLP Receptor GCGR	Metabolic Disease
Bamadutide (SAR425899) is a potent dual **glucagon-like peptide-1 receptor/glucagon receptor** agonist. Bamadutide (SAR425899) improves postprandial glucose control by significantly enhancing β-cell function and slowing glucose absorption rate in vivo. Bamadutide (SAR425899)can be used for type 2 diabetes research .

HY-P10032A

NN1177 TFA NNC9204-1177 TFA	GCGR Cytochrome P450 GLP Receptor	Metabolic Disease
NN1177 (NNC9204-1177) TFA is a long-acting **GLP-1/glucagon receptor** co-agonist. NN1177 TFA can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

HY-P10271

RG7697	GLP Receptor	Metabolic Disease
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC₅₀ of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .

HY-P990013

Gulgafafusp alfa	GCGR	Metabolic Disease
Gulgafafusp alfa is a human IgG2κ antibody targeting the glucagon-like peptide 1 receptor GLP1R .

HY-P0014

Liraglutide 20+ Cited Publications	GCGR GLP Receptor	Metabolic Disease
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

HY-P1144

Oxyntomodulin (bovine, porcine) Glucagon-37 (bovine, porcine)	GCGR	Metabolic Disease
Oxyntomodulin (bovine, porcine), a 37-amino acid peptide hormone, is a glucagon-like peptide 1 (GLP-1) receptor agonist .

HY-142162

LSN3318839	GCGR	Metabolic Disease
LSN3318839 is an orally efficacious positive allosteric modulator of the glucagon-like peptide-1 receptor (GLP-1R).

HY-13443

Exendin-4 Maximum Cited Publications 45 Publications Verification Exenatide	GCGR	Metabolic Disease
Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting *glucagon-like* peptide-1 receptor agonist with an IC₅₀ of 3.22 nM.

HY-13443A

Exendin-4 acetate Maximum Cited Publications 45 Publications Verification Exenatide acetate	GCGR	Metabolic Disease
Exendin-4 acetate (Exenatide acetate), a 39 amino acid peptide, is a long-acting *glucagon-like* peptide-1 receptor agonist with an IC₅₀ of 3.22 nM.

HY-12525

LGD-6972	GCGR	Metabolic Disease
LGD-6972 is a selective and orally active **glucagon receptor** antagonist. LGD-6972 has the potential for type 2 diabetes research .

HY-P1144A

Oxyntomodulin (bovine, porcine) (TFA) Glucagon-37 (bovine, porcine) (TFA)	GCGR	Metabolic Disease
Oxyntomodulin (bovine, porcine) TFA, a 37-amino acid peptide hormone, is a glucagon-like peptide 1 (GLP-1) receptor agonist .

HY-12525A

LGD-6972 sodium	GCGR	Metabolic Disease
LGD-6972 sodium is a selective and orally active **glucagon receptor** antagonist. LGD-6972 sodium has the potential for type 2 diabetes research .

HY-103546

BETP 1 Publications Verification	GCGR	Metabolic Disease
BETP is an agonist of **glucagon-like peptide-1 (GLP-1) receptor, with EC₅₀*s of 0.66 and 0.755 μM for human and rat GLP-1 receptor*, respectively.

HY-162435

GLP-1R agonist 20	GLP Receptor	Metabolic Disease
GLP-1R agonist 20 (Compound I-132) is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC₅₀ of 0.0162 nM .

Cat. No.	Product Name

HY-L040

Anti-diabetic Compound Library

776 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 776 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Cat. No.	Product Name	Type

HY-114118F

Semaglutide, FITC labeled	Fluorescent Dyes/Probes
Semaglutide, FITC labeled is a FITC labeled Semaglutide. Semaglutide, a long-acting GLP-1 alogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment .

Cat. No.	Product Name	Target	Research Area

HY-P3506

Retatrutide 1 Publications Verification LY3437943	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) is a triple agonist peptide of *the glucagon* receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .

HY-P3506A

Retatrutide TFA 1 Publications Verification LY3437943 TFA	GLP Receptor GCGR	Metabolic Disease
Retatrutide (LY3437943) TFA is a triple agonist peptide of *the glucagon* receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P4146A

Survodutide TFA BI 456906 TFA	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P3375

Mazdutide IBI-362; LY-3305677; OXM-3	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .

HY-P10327

PP18	GLP Receptor	Metabolic Disease
PP18 is a novel OXM-based dual GLP-1 and glucagon receptor agonist with EC₅₀ values of 0.487 nM target hGLP-1R and 0.188 nM target hGcgR .

HY-P3506B

Retatrutide acetate LY3437943 acetate	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) acetate is a triple agonist peptide of *the glucagon* receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC₅₀** values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .

HY-P3375A

Mazdutide TFA IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .

HY-P4672

(Met(O)27)-Glucagon (1-29) (human, rat, porcine)	GCGR	Metabolic Disease
(Met(O)27)-Glucagon (1-29) (human, rat, porcine) is a modified glucagon. (Met(O)27)-Glucagon (1-29) (human, rat, porcine) has the same maximum glucose-synthesizing activity in rat hepatocytes as native glucagon, but it is less potent, suggesting a crucial role of methionine in the binding of glucagon to its hepatic receptor .

HY-P1143

[Des-His1,Glu9]-Glucagon amide	GCGR	Metabolic Disease
[Des-His1,Glu9]-Glucagon amide is a potent and peptide antagonist of the **glucagon receptor, with a pA₂** of 7.2. [Des-His1,Glu9]-Glucagon amide is potentially useful in the study of the pathogenesis of diabetes .

HY-P1143A

[Des-His1,Glu9]-Glucagon amide TFA	GCGR	Metabolic Disease
[Des-His1,Glu9]-Glucagon amide TFA is a potent and peptide antagonist of the **glucagon receptor, with a pA₂** of 7.2. [Des-His1,Glu9]-Glucagon amide TFA is potentially useful in the study of the pathogenesis of diabetes .

HY-P3608

[Des-His1,Glu9] Glucagon	GCGR	Metabolic Disease
[Des-His1,Glu9] Glucagon is a potent glucagon receptor system peptide antagonist. [Des-His1,Glu9] Glucagon enhances the glucose-stimulated release of insulin from pancreatic islet cells. [Des-His1,Glu9] Glucagon can be used to research diabetes .

HY-P3388

Utreglutide	GCGR	Metabolic Disease
Utreglutide is a potent **glucagon-like peptide 1 (GLP-1) receptor** agonit .

HY-P10592

Bofanglutidum Bofanglutide	GLP Receptor	Metabolic Disease
Bofanglutide (Bofanglutidum) is a glucagon-like peptide 1 (GLP-1) receptor agonist .

HY-P10032

NN1177 NNC9204-1177	GCGR GLP Receptor Cytochrome P450	Metabolic Disease
NN1177 is a long-acting **GLP-1/glucagon receptor** co-agonist. NN1177 can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .

HY-P1145

Glucagon-like peptide 1 (1-37), human HuGLP-1	GCGR	Metabolic Disease
Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.

HY-P1145A

Glucagon-like peptide 1 (1-37), human TFA 1 Publications Verification HuGLP-1 TFA	GCGR	Metabolic Disease
Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor.

HY-P10018

Bamadutide SAR425899	GLP Receptor GCGR	Metabolic Disease
Bamadutide (SAR425899) is a potent dual **glucagon-like peptide-1 receptor/glucagon receptor** agonist. Bamadutide (SAR425899) improves postprandial glucose control by significantly enhancing β-cell function and slowing glucose absorption rate in vivo. Bamadutide (SAR425899)can be used for type 2 diabetes research .

HY-P10032A

NN1177 TFA NNC9204-1177 TFA	GCGR Cytochrome P450 GLP Receptor	Metabolic Disease
NN1177 (NNC9204-1177) TFA is a long-acting **GLP-1/glucagon receptor** co-agonist. NN1177 TFA can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

HY-P10271

RG7697	GLP Receptor	Metabolic Disease
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC₅₀ of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .

HY-P0014

Liraglutide 20+ Cited Publications	GCGR GLP Receptor	Metabolic Disease
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

HY-P1144

Oxyntomodulin (bovine, porcine) Glucagon-37 (bovine, porcine)	GCGR	Metabolic Disease
Oxyntomodulin (bovine, porcine), a 37-amino acid peptide hormone, is a glucagon-like peptide 1 (GLP-1) receptor agonist .

HY-13443

Exendin-4 Maximum Cited Publications 45 Publications Verification Exenatide	GCGR	Metabolic Disease
Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting *glucagon-like* peptide-1 receptor agonist with an IC₅₀ of 3.22 nM.

HY-13443A

Exendin-4 acetate Maximum Cited Publications 45 Publications Verification Exenatide acetate	GCGR	Metabolic Disease
Exendin-4 acetate (Exenatide acetate), a 39 amino acid peptide, is a long-acting *glucagon-like* peptide-1 receptor agonist with an IC₅₀ of 3.22 nM.

HY-P1144A

Oxyntomodulin (bovine, porcine) (TFA) Glucagon-37 (bovine, porcine) (TFA)	GCGR	Metabolic Disease
Oxyntomodulin (bovine, porcine) TFA, a 37-amino acid peptide hormone, is a glucagon-like peptide 1 (GLP-1) receptor agonist .

HY-P3491

Pegloxenatide PEX 168	GLP Receptor	Metabolic Disease
Pegloxenatide is a glucagon-like peptide-1 receptor (GLP-1 RA) agonist. Pegloxenatide can be used for type 2 diabetes research .

HY-P0165

Taspoglutide ITM077; R1583; BIM51077	GCGR	Metabolic Disease
Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC₅₀ value of 0.06 nM.

HY-P0119A

Lixisenatide acetate 2 Publications Verification	GCGR	Metabolic Disease
Lixisenatide acetate is a **glucagon-like peptide-1 (GLP-1) receptor** agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).

HY-P4407

(D-Asn28)-Exenatide	Peptides	Metabolic Disease
(D-Asn28)-Exenatide is an Exenatide (HY-13443) impurity. Exenatide is a long-acting glucagon-like peptide-1 receptor agonist .

HY-P4410

(D-Asp28)-Exenatide	Peptides	Metabolic Disease
(D-Asp28)-Exenatide is an Exenatide (HY-13443) impurity. Exenatide is a long-acting glucagon-like peptide-1 receptor agonist .

HY-114118

Semaglutide 4 Publications Verification	GCGR	Metabolic Disease
Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment.

HY-114118B

Semaglutide acetate 4 Publications Verification	GCGR	Metabolic Disease
Semaglutide acetate, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide acetate has the potential for type 2 diabetes treatment.

HY-P0120

Dulaglutide 1 Publications Verification LY2189265	GCGR	Metabolic Disease
Dulaglutide (LY2189265) is a glucagon-like peptide-1 (GLP-1) receptor agonist. Dulaglutide can be uesd for the research of type 2 diabetes (T2D) .

HY-114118A

Semaglutide TFA 4 Publications Verification	GCGR	Metabolic Disease
Semaglutide TFA, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide TFA has the potential for type 2 diabetes treatment.

HY-P2497

Exendin (5-39) 1 Publications Verification	GCGR	Neurological Disease
Exendin (5-39) is a potent glucagon-like peptide 1 (GLP-1) receptor antagonist. Exendin (5-39) improves memory impairment in β-amyloid protein-treated rats .

HY-P3366

Ecnoglutide XW003	GCGR	Metabolic Disease
Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-like peptide 1 (GLP-1) receptor agonist. Ecnoglutide can be used for research of T2DM and obesity .

HY-P1348

GLP-1 moiety from Dulaglutide	GCGR	Metabolic Disease
GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide which is a glucagon-like peptide 1 receptor (GLP-1) agonist, extracted from patent US 20160369010 A1.

HY-P10269

GZR18	GLP Receptor	Metabolic Disease
GZR18 is an analog of glucagon-like peptide-1 (GLP-1), which exhibits agonistic activity for GLP-1 receptor, with an EC₅₀ of 0.677 nM. GZR18 ameliorates type 2 diabetes .

HY-114118F

Semaglutide, FITC labeled	GCGR	Metabolic Disease
Semaglutide, FITC labeled is a FITC labeled Semaglutide. Semaglutide, a long-acting GLP-1 alogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment .

HY-13443R

Exendin-4 (Standard)	GCGR	Metabolic Disease
Exendin-4 (Standard) is the analytical standard of Exendin-4. This product is intended for research and analytical applications. Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting *glucagon-like* peptide-1 receptor agonist with an IC₅₀ of 3.22 nM.

HY-P1159

[D-p-Cl-Phe6,Leu17]-VIP	Peptides	Neurological Disease Inflammation/Immunology
[D-p-Cl-Phe6,Leu17]-VIP is a competitive and selective antagonist of vasoactive intestinal peptide (VIP) receptor, with the IC₅₀ of 125.8 nM. [D-p-Cl-Phe6,Leu17]-VIP has no activity on glucagon, secretin or GRF receptors .

HY-P0014S2

Liraglutide-13C6,15N TFA	Isotope-Labeled Compounds	Others
Liraglutide- ¹³C₆, ¹⁵N (TFA)is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus .

HY-P0014S1

Liraglutide-13C5,15N TFA	Isotope-Labeled Compounds	Others
Liraglutide- ¹³C₅, ¹⁵N (tetraTFA)is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus .

HY-P1159A

[D-p-Cl-Phe6,Leu17]-VIP TFA	Peptides	Neurological Disease Inflammation/Immunology
[D-p-Cl-Phe6,Leu17]-VIP TFA is a competitive and selective antagonist of vasoactive intestinal peptide (VIP) receptor, with the IC₅₀ of 125.8 nM. [D-p-Cl-Phe6,Leu17]-VIP TFA has no activity on glucagon, secretin or GRF receptors .

HY-P10318

SHR-2042	GLP Receptor	Endocrinology
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .

HY-P10302

GLP-1R/GIPR agonist-1	GLP Receptor Insulin Receptor	Metabolic Disease
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-106103

Seglitide MK-678; L-363586	Somatostatin Receptor	Neurological Disease Metabolic Disease
Seglitide (MK-678) is a potent, orally active somatostatin receptor 2 (SSTR₂) agonist, and also a competitive antagonist of SSTR₁₄, SSTR₂₅, and SSTR₂₈. Seglitide has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide can be used for research on diabetes .

HY-106103A

Seglitide acetate MK 678 acetate; L 36358 acetate	Somatostatin Receptor	Neurological Disease Metabolic Disease
Seglitide acetate (MK 678; L 36358 acetate) is a potent, orally active somatostatin receptor 2 (SSTR₂) agonist, and also a competitive antagonist of SSTR₁₄, SSTR₂₅, and SSTR₂₈. Seglitide acetate has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide acetate can be used for research on diabetes .

HY-P1141

GLP-1(9-36)amide	GCGR	Metabolic Disease
GLP-1(9-36)amide is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide acts as an antagonist to the human pancreatic GLP-1 receptor .

Cat. No.	Product Name	Target	Research Area

HY-P99383

Volagidemab REMD-477; AMG-477	GCGR	Metabolic Disease
Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D) .

HY-P99357

Crotedumab REGN1193; Anti-GCGR Reference Antibody (crotedumab)	GCGR	Metabolic Disease
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a K_D of 0.1 nM. Crotedumab can be used for the research of diabetes .

HY-P990013

Gulgafafusp alfa	GCGR	Metabolic Disease
Gulgafafusp alfa is a human IgG2κ antibody targeting the glucagon-like peptide 1 receptor GLP1R .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0630

Shanzhiside methyl ester	Structural Classification Iridoids Terpenoids Labiatae Phaseolus lunatus L. Source classification Plants	GCGR
Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule **glucagon-like peptide-1 (GLP-1) receptor** agonist and has the ability to induce anti-allodynic tolerance .

HY-119739

Skyrin	Ventilago leiocarpa Benth. Quinones Structural Classification Anthraquinones Source classification Plants Rhamnaceae	GCGR
Skyrin is an anthraquinone compound that can be isolated from almond fruit. Skyrin is a receptor-selective *glucagon* antagonist. Skyrin can inhibit the growth of tumor cells .

HY-N2452

Cochinchinenin C	other families Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Plants Disease Research Fields	GCGR
Cochinchinenin C is a nonpolypeptide agonist of **glucagon-like peptide-1 (GLP-1) receptor**. Cochinchinenin C can be used for the research of diabetes .

HY-N0630R

Shanzhiside methyl ester (Standard)	Structural Classification Iridoids Terpenoids Labiatae Phaseolus lunatus L. Source classification Plants	GCGR
Shanzhiside methyl ester (Standard) is the analytical standard of Shanzhiside methyl ester. This product is intended for research and analytical applications. Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and has the ability to induce anti-allodynic tolerance .

HY-113513

5-HEPE	Microorganisms Source classification	Others
5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.

Recombinant Proteins Recommended:

Glucagon Receptor

Species:	Human (3) Mouse (1)
Tag:	His (3) SUMO (1) Myc (2) Fc (1)
Source:	HEK293 (3) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P700411

	GCGR Protein, Human (HEK293, N-His, C-Myc) Glucagon Receptor; GGR; GL-R; FLJ97182; MGC138246	Human	HEK293
	The GCGR protein is a glucagon G protein-coupled receptor that is critical in blood glucose regulation and actively controls hepatic glucose production. It promotes glycogen hydrolysis and gluconeogenesis, which are critical for the fasting response. GCGR Protein, Human (HEK293, N-His, C-Myc) is the recombinant human-derived GCGR protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag. The total length of GCGR Protein, Human (HEK293, N-His, C-Myc) is 111 a.a., with molecular weight of ~35 kDa.

HY-P72206

	GLP1R Protein, Mouse (His-SUMO) Glp1r; Glucagon-like peptide 1 Receptor; GLP-1 Receptor; GLP-1-R; GLP-1R	Mouse	E. coli
	GLP1R protein, a G-protein coupled receptor, binds to GLP-1, activating adenylyl cyclase and increasing intracellular cAMP levels. This interaction regulates insulin secretion and maintains glucose homeostasis. GLP1R can also form dimers with GIPR, suggesting complex regulatory mechanisms and interactions with other receptors. GLP1R Protein, Mouse (His-SUMO) is the recombinant mouse-derived GLP1R protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag. The total length of GLP1R Protein, Mouse (His-SUMO) is 124 a.a., with molecular weight of ~30.4 kDa.

HY-P70352

	GLP1R Protein, Human (HEK293, Fc) rHuGlucagon-like peptide 1 Receptor/GLP1R, Fc; Glucagon-like peptide 1 Receptor; GLP-1 Receptor; GLP-1-R	Human	HEK293
	The GLP1R protein is a G protein-coupled receptor for glucagon-like peptide 1 (GLP-1), which upon ligand binding activates adenylyl cyclase and increases cAMP levels. This interaction critically regulates insulin secretion, affecting cellular responses and metabolic processes associated with GLP-1 signaling. GLP1R Protein, Human (HEK293, Fc) is the recombinant human-derived GLP1R protein, expressed by HEK293 , with C-hFc labeled tag. The total length of GLP1R Protein, Human (HEK293, Fc) is 122 a.a., with molecular weight of 50-70 kDa.

HY-P700468

	GLP1R Protein, Human (HEK293, N-His, C-Myc) rHuGlucagon-like peptide 1 Receptor/GLP1R, Fc; Glucagon-like peptide 1 Receptor; GLP-1 Receptor; GLP-1-R	Human	HEK293
	The GLP1R protein is a G protein-coupled receptor for glucagon-like peptide 1 (GLP-1), which upon ligand binding activates adenylyl cyclase and increases cAMP levels. This interaction critically regulates insulin secretion, affecting cellular responses and metabolic processes associated with GLP-1 signaling. GLP1R Protein, Human (HEK293, N-His, C-Myc) is the recombinant human-derived GLP1R protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag. The total length of GLP1R Protein, Human (HEK293, N-His, C-Myc) is 122 a.a., with molecular weight of 33 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure